Dapagliflozin + Placebo

ApprovedCompleted

1 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Heart Failure，Congestive

Conditions

Heart Failure，Congestive

Trial Timeline

Feb 15, 2021 → Oct 28, 2024

NCT ID

NCT04869124

About Dapagliflozin + Placebo

Dapagliflozin + Placebo is a approved stage product being developed by AstraZeneca for Heart Failure，Congestive. The current trial status is completed. This product is registered under clinical trial identifier NCT04869124. Target conditions include Heart Failure，Congestive.

What happened to similar drugs?

20 of 20 similar drugs in Heart Failure，Congestive were approved

Approved (20) Terminated (3) Active (0)

✅SGLT2i, beta blocker, ARNI, MRA, MTDEli LillyApproved

✅Prasugrel 10 mg daily x 2 weeks + Clopidogrel 75 mg daily x 2 weeksDaiichi SankyoApproved

✅ConivaptanAstellas PharmaApproved

✅RegadenosonAstellas PharmaApproved

✅Regadenoson + GadoliniumAstellas PharmaApproved

✅regadenosonAstellas PharmaApproved

✅Tacrolimus granules + Tacrolimus capsulesAstellas PharmaApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04792190	Approved	Completed	Jul 27, 2021	Jun 30, 2023	Atrial Fibrillation
NCT04869124	Approved	Completed	Feb 15, 2021	Oct 28, 2024	Heart Failure，Congestive
NCT04564742	Phase 3	Completed	Dec 22, 2020	Jul 5, 2023	Acute Myocardial Infarction
NCT04363697	Approved	Completed	Sep 24, 2020	Jun 2, 2025	Acute Heart Failure
NCT04475042	Phase 2	UNKNOWN	Jul 1, 2020	May 1, 2022	Heart Failure, Diastolic
NCT02981966	Approved	Completed	May 23, 2019	May 31, 2023	Diabetes Mellitus, Type 2
NCT03619213	Phase 3	Completed	Aug 27, 2018	Mar 27, 2022	Heart Failure With Preserved Ejection Fraction
NCT03387683	Approved	Completed	Feb 28, 2018	Mar 19, 2019	Diabetes Mellitus Type 2
NCT02956811	Approved	Completed	Feb 14, 2017	Apr 2, 2019	Type 2 Diabetes
NCT03036124	Phase 3	Completed	Feb 8, 2017	Jul 17, 2019	Chronic Heart Failure With Reduced Ejection Fraction (HFrEF)
NCT03036150	Phase 3	Completed	Feb 2, 2017	Jun 12, 2020	Chronic Kidney Disease
NCT02796170	Approved	Completed	Mar 1, 2016	Aug 1, 2020	Type 2 Diabetes
NCT02520518	Phase 2	Terminated	Aug 1, 2015	May 1, 2017	Weight Loss
NCT02459353	Approved	Completed	Aug 1, 2015	May 1, 2017	Type 2 Diabetes Mellitus
NCT02371187	Phase 2	Completed	Jun 1, 2015	Jan 1, 2018	Physical Activity
NCT02426541	Approved	Completed	Mar 23, 2015	Apr 28, 2016	Type 2 Diabetes Mellitus
NCT01392677	Phase 3	Completed	Oct 1, 2011	Aug 1, 2013	Type 2 Diabetes Mellitus
NCT01042977	Phase 3	Completed	Mar 1, 2010	Dec 1, 2012	Type 2 Diabetes Mellitus
NCT01031680	Phase 3	Completed	Feb 1, 2010	Dec 1, 2012	Type 2 Diabetes Mellitus
NCT00984867	Phase 3	Completed	Oct 1, 2009	Sep 1, 2011	Type 2 Diabetes

Competing Products

20 competing products in Heart Failure，Congestive

See all competitors

Product	Company	Stage	Hype Score
mRNA-0184	Moderna	Phase 1	0
IV diuretic	Nuwellis	Pre-clinical	16
IV Loop Diuretics	Nuwellis	Pre-clinical	23
Stepped pharmacologic care	Nuwellis	Phase 3	30
IV Loop Diuretics (LD)	Nuwellis	Pre-clinical	8
TRV120027 + Normal Saline	Trevena	Phase 1	19
TRV027 Dose #1 + TRV027 Dose #2 + TRV027 Dose #3 + Placebo	Trevena	Phase 2	25
TRV120027 + Placebo	Trevena	Phase 1/2	22
Ilofotase alfa + Placebo	AM-Pharma	Phase 2	25
INXN-4001	Precigen	Phase 1	23
LY3461767 + Placebo	Eli Lilly	Phase 1	29
SGLT2i, beta blocker, ARNI, MRA, MTD	Eli Lilly	Approved	43
Pactimibe, CS-505	Daiichi Sankyo	Phase 2	35
Prasugrel 10 mg daily x 2 weeks + Clopidogrel 75 mg daily x 2 weeks	Daiichi Sankyo	Approved	43
olmesartan medoxomil + candesartan cilexetil placebo + olmesartan medoxomil placebo + candesartan cilexetil	Daiichi Sankyo	Phase 3	32
Olmesartan	Daiichi Sankyo	Phase 3	40
Carperitide + Placebo	Daiichi Sankyo	Phase 2	35
Edoxaban	Daiichi Sankyo	Pre-clinical	22
Regadenoson	Astellas Pharma	Phase 1	29
Advagraf + Prograf	Astellas Pharma	Phase 2	35